OncoMatch/Clinical Trials/NCT06478693

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Is NCT06478693 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MT-303 and MT-303 +Atezolizumab + Bevacizumab for hepatocellular carcinoma.

Phase 1RecruitingMyeloid TherapeuticsNCT06478693Data as of May 2026

Treatment: MT-303 · MT-303 +Atezolizumab + Bevacizumab — This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Biomarker criteria

Required: GPC3 expression

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Liver function

child-pugh score: class a

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify